ICHNO-ECHNO 2022 - Abstract Book

S40

ICHNO-ECHNO 2022

Results 207 GPs participated in this study. Seventy-two percent recognized HPV as a risk factor for OPC, 76.3% of which were aware of the increasing incidence rate of HPV-associated OPC. In contrast, 35.3% of participants knew that HPV-associated OPC patients are more often male, and just over half (53.6%) of the participants were aware of the younger age of these patients. Conclusion More than a quarter of GPs in The Netherlands are unaware of HPV as a causative factor for OPC. Furthermore, there is a gap in knowledge on HPV-associated OPC patient characteristics. In a previous study, we also showed a lacking awareness within the general public.[1] Further training on these topics could improve disease recognition, the HPV-vaccination rate and ultimately patient survival. [1] Verhees F, Demers I, Schouten LJ, Lechner M, Speel EJ, Kremer B. Public awareness of the association between human papillomavirus and oropharyngeal cancer. Eur J Public Health, 2021 Jun [ePub ahead of print]

PO-0072 HPV in sinonasal squamous cell carcinoma : a better prognosis ?

A. Tendron 1 , A. Moya-Plana 2 , M. Classe 3 , P. Gorphe 2

1 Gustave Roussy , Head and Neck surgery/ Pathology, Villejuif, France; 2 Gustave Roussy , Head and Neck surgery, Villejuif, France; 3 Gustave Roussy , Pathology, VIllejuif, France Purpose or Objective Sinonasal squamous cell carcinomas (SNSCC) are rare cancers with a poor prognosis despite multimodal treatment, most often including decaying surgery and / or radio chemotherapy. Human Papillomavirus (HPV) is a well known carcinogen in the oropharynx. It has been shown to be present in some sinonasal carcinomas, , its implication in SNSCC is still poorly decribed. HPV associated-SCC of the oropharynx respond particularly well to radiochemotherapy. The radiochemiosensitivity of these tumors could constitute a prognostic factor in SNSCC. Many studies have searched for the presence of HPV in sinonasal tumors. However, the detection techniques were inconstant. Today the gold standard for proving HPV-induced status is the detection of E6 E7 RNA. The objective of this study was to investigate the incidence of HPV and its impact on survival, clinical presentation and the tumor immune microenvironment in SNSCC. Materials and Methods All patients with SNSCC treated at Gustave Roussy Institute from January 1997 to March 2021 for whom tumor samples were available were selected. P16 status was assessed by immunohistochemistry for all cases. For P16+ and P16 doubtful samples, a high-risk HPV RNA in situ hybridization and HPV DNA PCR was carried out. A study of the immune microenvironment exploring the expression of PDL1, CD8, and FOXP3 by multiplex immunohistochemistry (IHCm) was performed for all cases. IHCm were analyzed with semi-automated image analysis software (QUPATH). Results Among the 59 patients included, 11 cases were P16+, 5 cases were P16 doubtful. A total of 9 cases were confirmed as HPV+ by RNAscope (6 P16+ and 3 P16 doubtful). The two groups were comparable for age, sex, TNM stage and treatment options. HPV sub-type were HPV 16, 18 and 33. The HPV+ tumours were more often located to the nasal cavities (n = 8/9) while the HPV- was predominant in the sinuses (n = 40/50). The overall survival of the HPV+ group was significantly better (p = 0.022) and the progression-free survival of the HPV+ and HPV- groups did not differ (p = 0.073). Disease control tended to be better in the HPV+ group (p = 0.27). The microenvironment study did not find any significant difference in number or topography for CD8+ T cells and Treg. The HPV+ group tended to express a higher CPS score (p = 0.051). Conclusion HPV + SNSCCs represent 15.2% of all SNSCCs in our cohort. As with the oropharynx, the induced HPV statut seems to have an impact on the presentation and clinical course with a better prognosis for HPV associated SNSCC. P16 statut must be interpreted with caution since some P16 doubtful cases were finallyRNA +. The immune microenvironment does not appear to be different according to HPV. These results are to be confirmed on a larger cohort.

PO-0073 HPV-positive squamous cell carcinoma of the oropharynx: Real world data from a UK cancer centre

J. Helbrow 1 , J. Hesford 1 , J. Graby 2 , A. Cook 1 , S. Hopcroft 3 , W. Grant 1

1 Gloucestershire Hospitals NHS Foundation Trust, Oncology, Cheltenham, United Kingdom; 2 Royal United Hospitals Bath NHS Foundation Trust, Research and Development , Bath, United Kingdom; 3 Gloucestershire Hospitals NHS Foundation Trust, Pathology, Gloucester, United Kingdom Purpose or Objective Long-term survival for radically-treated HPV-positive squamous cell carcinoma of the oropharynx (HPV+ SCCOP) is reported to exceed 80%, though aggressive and atypical disease patterns have been observed. We examine outcomes from our UK Cancer Centre.